logo
  Join        Login             Stock Quote

Singulex Sets IPO Pricing Between $15 And $17

 October 24, 2012 11:28 AM


(By Balachander) Singulex, a developer of tests to diagnose chronic diseases, has set the terms for its initial public offering (IPO).

The Alameda, California-based company has launched an IPO of roughly 4.37 million shares, with an estimated pricing between $15.00 and $17.00 each.

At the midpoint of the proposed range, Singulex will have an initial market capitalization of roughly $246 million.

The company expects net proceeds from the offering to be roughly $62.3 million.

The company's advanced cardiovascular disease (CVD) monitoring services include enhanced cardiovascular profiling featuring ultrasensitive Sgx HD immunoassays, a personalized wellness program, and online interactive management tools. The company launched its Advanced CVD Monitoring services in July 2010.

[Related -Thoughts on MetLife and AIG]

Singulex is developing a second generation digital immunoassay monitoring platform, which is currently in the design and development stage, with expected prototype development commencing in the first half of 2013.

The company said it expect this system to be a higher-throughput, fully-automated platform focused on high precision immunoassays for advanced management of CVD and other chronic diseases.

The company, which was formed in 1997, posted a net loss of $10.3 million on revenue of $20.5 million for the six months ended June 30, 2012.

For the year ended December 31, 2011, the company lost $12.5 million on revenue of  $24.8 million.

Investors in the company include: Fisk Ventures, OrbiMed Advisors, JAFCO and Prolog Ventures.

Singulex proposes to list on the New York Stock Exchange under the symbol "SGLX."

UBS Investment Bank and Piper Jaffray are the joint bookrunners on the offering.

Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageThoughts on MetLife and AIG

In some ways, this is a boring time in insurance investing.  A lot of companies seem cheap on a book and/or read on...

article imageA 2016 Recession Would Be Different

If the US or the Eurozone entered a recession this year, a few macroeconomic variables would look very read on...

article imageWhat's Next For Chipotle?

After stumbling badly on negative publicity about foodborne illness at some of its restaurants, the fast read on...

article imageHow Fast Can These Stocks Make You A Millionaire?

These days it seems as if the market doesn't know whether it wants to break through fears of higher rates read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center

Related Articles:

What's Next For Chipotle?
More Articles on: Medical



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.